Spots Global Cancer Trial Database for Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer
Official Title: Phase 1 Trial of Oral Karenitecin® in Patients With Solid Tumors"
Study ID: NCT00097903
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the maximum safe dose of orally administered Karenitecin (BNP1350) in patients with solid tumors.
Detailed Description: Initially, the safety, side effects and recommended phase 2 dose of oral Karenitecin in patients with advanced solid tumors will be determined. When the recommended phase 2 dose has been determined, the specified dose will be used to determine if Karenitecin is effective in the treatment of patients with relapsed or refractory non-small cell lung cancer.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Ellis Fischel Cancer Center, Columbia, Missouri, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
